Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trevena, a drug discovery company focused on developing pharmaceutical products targeting G-protein coupled receptors, has closed a $24 million series A financing.
Subscribe to our email newsletter
Alta Partners and Healthcare Ventures led the round as part of an investor syndicate that included New Enterprise Associates and Polaris Venture Partners. The company will use the funds to progress its drug discovery portfolio.
Maxine Gowen, president and CEO of Trevena, said: “Trevena’s mission will be to utilize a state of the art approach to discover and develop novel GPCR-targeted medicines for patients.”